Thermo Fisher Scientific Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marc N. Casper
- Full Time Employees
- 125,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 168 Third Avenue Waltham MA United States of America 02451
- IPO Date
- Mar 17, 1980
- CIK
- 0000097745
- Website
- thermofisher.com
- Similar Companies
- Business
- Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.
West Pharma names former Thermo Fisher executive Lagarde as CEO
Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026
Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?
Thermo Fisher Scientific Inc (TMO) Stock Up 6.8% and Still Undervalued -- GF Score: 83/100
Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
TMO Fairly Valued by DCF at $478
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
Thermo Fisher Scientific Announces Quarterly Dividend
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Amazon, McDonald Surge Into Jefferies Top Picks Broadcom as Gets Cut
Jefferies updates its list of highest-conviction Buy-rated stocks
Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle
TMO DCF Analysis: Intrinsic Value $478 vs Price $465
Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials
International Markets and Thermo Fisher (TMO): A Deep Dive for Investors
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing
TMO Fairly Valued by DCF at $478
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies
Thermo Fisher Scientific to Host Investor Day